Final Human trial of Covid-19 vaccine in July by Moderna Inc
Shikha Chaurasia
Chicago (USA), June 13, 2020: Moderna Inc., a US-based company, on Thursday said that they will begin phase 3 human trials with 30,000 volunteers to test its mRNA-1273 vaccine against SARS-Cov-2 virus in July.
What amount of dosage is going to be used?
Moderna has selected a 100-microgram dosage to be used for the final phase study. This is a safe amount and can be tested on a large number of people to monitor the enhancement in immunity and to reduce the adverse effects of the vaccine.
The company is in collaboration with a Swiss drug-making company Lonza. Together it is said that they will be able to manufacture around 500 million doses per year and if everything goes well, they are positive to be able to manufacture around 1 billion doses from 2021.
What is the main aim of the study?
The main agenda of the company will be to prevent the symptomatic patient from getting infected with Covid-19 and the secondary goal will be to obstruct the spreading of severe diseases to keep people out of the hospital.
Till now there have been 77.5 lakh cases of COVID19 across the world, out of which 4.2 lakh people have died while 39.7 lakh have recovered. The others are still undergoing treatment. The world is expectantly waiting for a vaccine which will help prevent the virus from infecting people.
